A great deal of our research has gone into developing an alternative to Bone-marrow derived stem cells. Since perinatal stem cells are immunologically naive and readily available from literally hundreds of donors every day, we feel this source will eventually replace Bone-marrow as the preferred source of mesenchymal stem cells
We have developed a novel human, Mesenchymal stromal cell line from term Amniotic Tissue membrane. Thus far, the cell line has been characterized as being CD 44+ and CD117- (c-kit), and also display cell markers for both fibroblasts (beta subunit of prolyl 4-hydroxylase) and Nestin (pictured above) .
The cell line has been passaged for at least 12 times over 3 months without loss of non-differentiated morphology.
Hemacell Perfusion can also supply a propriety growth medium for this cell line as well as a protocol which induces neuronal differentiation.
Cells are available either cryopreserved at Passage 1 or as a monolayer culture.